<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Hepatol Int</journal-id><journal-id journal-id-type="iso-abbrev">Hepatol Int</journal-id><journal-id journal-id-type="pmc-domain-id">3814</journal-id><journal-id journal-id-type="pmc-domain">phenaturepg</journal-id><journal-title-group><journal-title>Hepatology International</journal-title></journal-title-group><issn pub-type="ppub">1936-0533</issn><issn pub-type="epub">1936-0541</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer Nature - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10042416</article-id><article-id pub-id-type="pmcid-ver">PMC10042416.1</article-id><article-id pub-id-type="pmcaid">10042416</article-id><article-id pub-id-type="pmcaiid">10042416</article-id><article-id pub-id-type="pmid">36973633</article-id><article-id pub-id-type="doi">10.1007/s12072-023-10506-z</article-id><article-id pub-id-type="publisher-id">10506</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-na&#239;ve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chang</surname><given-names initials="TS">Te-Sheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="CF">Chung-Feng</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kuo</surname><given-names initials="HT">Hsing-Tao</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lo</surname><given-names initials="CC">Ching-Chu</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="CW">Chien-Wei</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chong</surname><given-names initials="LW">Lee-Won</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cheng</surname><given-names initials="PN">Pin-Nan</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yeh</surname><given-names initials="ML">Ming-Lun</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Peng</surname><given-names initials="CY">Cheng-Yuan</given-names></name><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cheng</surname><given-names initials="CY">Chien-Yu</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="JF">Jee-Fu</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bair</surname><given-names initials="MJ">Ming-Jong</given-names></name><xref ref-type="aff" rid="Aff16">16</xref><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="CL">Chih-Lang</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="CC">Chi-Chieh</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="SJ">Szu-Jen</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hsieh</surname><given-names initials="TY">Tsai-Yuan</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="TH">Tzong-Hsi</given-names></name><xref ref-type="aff" rid="Aff22">22</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="PL">Pei-Lun</given-names></name><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="WC">Wen-Chih</given-names></name><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="CL">Chih-Lin</given-names></name><xref ref-type="aff" rid="Aff25">25</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Su</surname><given-names initials="WW">Wei-Wen</given-names></name><xref ref-type="aff" rid="Aff26">26</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="SS">Sheng-Shun</given-names></name><xref ref-type="aff" rid="Aff27">27</xref><xref ref-type="aff" rid="Aff28">28</xref><xref ref-type="aff" rid="Aff29">29</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="CC">Chia-Chi</given-names></name><xref ref-type="aff" rid="Aff30">30</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="JT">Jui-Ting</given-names></name><xref ref-type="aff" rid="Aff31">31</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mo</surname><given-names initials="LR">Lein-Ray</given-names></name><xref ref-type="aff" rid="Aff32">32</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="CT">Chun-Ting</given-names></name><xref ref-type="aff" rid="Aff21">21</xref><xref ref-type="aff" rid="Aff33">33</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="YH">Yi-Hsiang</given-names></name><xref ref-type="aff" rid="Aff34">34</xref><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chang</surname><given-names initials="CC">Chun-Chao</given-names></name><xref ref-type="aff" rid="Aff36">36</xref><xref ref-type="aff" rid="Aff37">37</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="CS">Chia-Sheng</given-names></name><xref ref-type="aff" rid="Aff38">38</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="GY">Guei-Ying</given-names></name><xref ref-type="aff" rid="Aff39">39</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kao</surname><given-names initials="CN">Chien-Neng</given-names></name><xref ref-type="aff" rid="Aff40">40</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tai</surname><given-names initials="CM">Chi-Ming</given-names></name><xref ref-type="aff" rid="Aff41">41</xref><xref ref-type="aff" rid="Aff42">42</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="CJ">Chun-Jen</given-names></name><xref ref-type="aff" rid="Aff43">43</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="MH">Mei-Hsuan</given-names></name><xref ref-type="aff" rid="Aff44">44</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tsai</surname><given-names initials="PC">Pei-Chien</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dai</surname><given-names initials="CY">Chia-Yen</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kao</surname><given-names initials="JH">Jia-Horng</given-names></name><xref ref-type="aff" rid="Aff43">43</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="HC">Han-Chieh</given-names></name><xref ref-type="aff" rid="Aff34">34</xref><xref ref-type="aff" rid="Aff35">35</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chuang</surname><given-names initials="WL">Wang-Long</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="CY">Chi-Yi</given-names></name><xref ref-type="aff" rid="Aff45">45</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tseng</surname><given-names initials="KC">Kuo-Chih</given-names></name><xref ref-type="aff" rid="Aff46">46</xref><xref ref-type="aff" rid="Aff47">47</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1646-9519</contrib-id><name name-style="western"><surname>Hung</surname><given-names initials="CH">Chao-Hung</given-names></name><address><email>chh4366@yahoo.com.tw</email></address><xref ref-type="aff" rid="Aff48">48</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8145-1900</contrib-id><name name-style="western"><surname>Yu</surname><given-names initials="ML">Ming-Lung</given-names></name><address><email>fish6069@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff15">15</xref><xref ref-type="aff" rid="Aff48">48</xref><xref ref-type="aff" rid="Aff49">49</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.454212.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 1756 1410</institution-id><institution>Division of Hepatogastroenterology, Department of Internal Medicine, </institution><institution>Chang Gung Memorial Hospital, </institution></institution-wrap>Chiayi, Taiwan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.145695.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1798 0922</institution-id><institution>College of Medicine, </institution><institution>Chang Gung University, </institution></institution-wrap>Taoyuan, Taiwan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.412027.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0620 9374</institution-id><institution>Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, </institution><institution>Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution>Ph.D. Program in Translational Medicine, College of Medicine, </institution><institution>Kaohsiung Medical University, Academia Sinica, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.413876.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 9255</institution-id><institution>Division of Gastroenterology and Hepatology, Department of Internal Medicine, </institution><institution>Chi Mei Medical Center, </institution></institution-wrap>Yongkang District, Tainan, Taiwan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.452771.2</institution-id><institution>Division of Gastroenterology, Department of Internal Medicine, </institution><institution>St. Martin De Porres Hospital, </institution></institution-wrap>Chiayi, Taiwan </aff><aff id="Aff7"><label>7</label>Division of Gastroenterology, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.415755.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0573 0483</institution-id><institution>Division of Hepatology and Gastroenterology, Department of Internal Medicine, </institution><institution>Shin Kong Wu Ho-Su Memorial Hospital, </institution></institution-wrap>Taipei, Taiwan </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.256105.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 1063</institution-id><institution>School of Medicine, </institution><institution>Fu-Jen Catholic University, </institution></institution-wrap>New Taipei City, Taiwan </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.412040.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0639 0054</institution-id><institution>Division of Gastroenterology and Hepatology, Department of Internal Medicine, </institution><institution>National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, </institution></institution-wrap>Tainan, Taiwan </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution>Center for Liquid Biopsy and Cohort Research, </institution><institution>Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution>Center for Digestive Medicine, Department of Internal Medicine, </institution><institution>China Medical University Hospital, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.254145.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0083 6092</institution-id><institution>School of Medicine, </institution><institution>China Medical University, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.416911.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0639 1727</institution-id><institution>Division of Infectious Diseases, Department of Internal Medicine, </institution><institution>Taoyuan General Hospital, Ministry of Health and Welfare, </institution></institution-wrap>Taoyuan, Taiwan </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution>Hepatitis Research Center, College of Medicine, </institution><institution>Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="GRID">grid.413593.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0573 007X</institution-id><institution>Division of Gastroenterology, Department of Internal Medicine, </institution><institution>Taitung Mackay Memorial Hospital, </institution></institution-wrap>Taitung, Taiwan </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="GRID">grid.452449.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 1762 5613</institution-id><institution>Mackay Medical College, </institution></institution-wrap>New Taipei City, Taiwan </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="GRID">grid.454209.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0639 2551</institution-id><institution>Liver Research Unit, Department of Hepato-Gastroenterology and Community Medicine Research Center, </institution><institution>Chang Gung Memorial Hospital at Keelung, College of Medicine, Chang Gung University, </institution></institution-wrap>Keelung, Taiwan </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="GRID">grid.452796.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0634 3637</institution-id><institution>Department of Gastroenterology, Division of Internal Medicine, </institution><institution>Show Chwan Memorial Hospital, </institution></institution-wrap>Changhua, Taiwan </aff><aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="GRID">grid.417380.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0622 9252</institution-id><institution>Division of Gastroenterology, Department of Internal Medicine, </institution><institution>Yuan&#8217;s General Hospital, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="GRID">grid.278244.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0638 9360</institution-id><institution>Division of Gastroenterology, Department of Internal Medicine, </institution><institution>Tri&#8209;Service General Hospital, National Defense Medical Center, </institution></institution-wrap>Taipei, Taiwan </aff><aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="GRID">grid.414746.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0604 4784</institution-id><institution>Division of Gastroenterology and Hepatology, </institution><institution>Far Eastern Memorial Hospital, </institution></institution-wrap>New Taipei City, Taiwan </aff><aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="GRID">grid.413876.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 9255</institution-id><institution>Division of Gastroenterology and Hepatology, Department of Internal Medicine, </institution><institution>Chi Mei Medical Center, </institution></institution-wrap>Liouying, Tainan, Taiwan </aff><aff id="Aff24"><label>24</label>Wen-Chih Wu Clinic, Fengshan, Kaohsiung, Taiwan </aff><aff id="Aff25"><label>25</label>Department of Gastroenterology, Renai Branch, Taipei City Hospital, Taipei, Taiwan </aff><aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="GRID">grid.413814.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 7372</institution-id><institution>Department of Gastroenterology and Hepatology, </institution><institution>Changhua Christian Hospital, </institution></institution-wrap>Changhua, Taiwan </aff><aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="GRID">grid.410764.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0573 0731</institution-id><institution>Division of Gastroenterology and Hepatology, Department of Internal Medicine, </institution><institution>Taichung Veterans General Hospital, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff28"><label>28</label><institution-wrap><institution-id institution-id-type="GRID">grid.260542.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0532 3749</institution-id><institution>Institute of Biomedical Sciences, </institution><institution>National Chung Hsing University, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff29"><label>29</label><institution-wrap><institution-id institution-id-type="GRID">grid.260542.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0532 3749</institution-id><institution>Department of Post-Baccalaureate Medicine, College of Medicine, </institution><institution>National Chung Hsing University, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff30"><label>30</label><institution-wrap><institution-id institution-id-type="GRID">grid.481324.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0404 6823</institution-id><institution>Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and School of Medicine, Tzu Chi University, </institution></institution-wrap>Taipei, Taiwan </aff><aff id="Aff31"><label>31</label><institution-wrap><institution-id institution-id-type="GRID">grid.413535.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0627 9786</institution-id><institution>Liver Center, </institution><institution>Cathay General Hospital, </institution></institution-wrap>Taipei, Taiwan </aff><aff id="Aff32"><label>32</label><institution-wrap><institution-id institution-id-type="GRID">grid.410770.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0639 1057</institution-id><institution>Division of Gastroenterology, </institution><institution>Tainan Municipal Hospital (Managed By Show Chwan Medical Care Corporation), </institution></institution-wrap>Tainan, Taiwan </aff><aff id="Aff33"><label>33</label><institution-wrap><institution-id institution-id-type="GRID">grid.260565.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0634 0356</institution-id><institution>Division of Gastroenterology, Department of Internal Medicine, </institution><institution>Tri&#8209;Service General Hospital Penghu Branch, National Defense Medical Center, </institution></institution-wrap>Taipei, Taiwan </aff><aff id="Aff34"><label>34</label><institution-wrap><institution-id institution-id-type="GRID">grid.278247.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0604 5314</institution-id><institution>Division of Gastroenterology and Hepatology, Department of Medicine, </institution><institution>Taipei Veterans General Hospital, </institution></institution-wrap>Taipei, Taiwan </aff><aff id="Aff35"><label>35</label><institution-wrap><institution-id institution-id-type="GRID">grid.260539.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2059 7017</institution-id><institution>Institute of Clinical Medicine, School of Medicine, </institution><institution>National Yang-Ming Chiao Tung University, </institution></institution-wrap>Taipei, Taiwan </aff><aff id="Aff36"><label>36</label><institution-wrap><institution-id institution-id-type="GRID">grid.412897.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0639 0994</institution-id><institution>Division of Gastroenterology and Hepatology, Department of Internal Medicine, </institution><institution>Taipei Medical University Hospital, </institution></institution-wrap>Taipei, Taiwan </aff><aff id="Aff37"><label>37</label><institution-wrap><institution-id institution-id-type="GRID">grid.412896.0</institution-id><institution-id institution-id-type="ISNI">0000 0000 9337 0481</institution-id><institution>Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, </institution><institution>Taipei Medical University, </institution></institution-wrap>Taipei, Taiwan </aff><aff id="Aff38"><label>38</label>Yang Ming Hospital, Chiayi, Taiwan </aff><aff id="Aff39"><label>39</label><institution-wrap><institution-id institution-id-type="GRID">grid.454740.6</institution-id><institution>Penghu Hospital, Ministry of Health and Welfare, </institution></institution-wrap>Penghu, Taiwan </aff><aff id="Aff40"><label>40</label><institution-wrap><institution-id institution-id-type="GRID">grid.412094.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 7815</institution-id><institution>National Taiwan University Hospital Hsin-Chu Branch, </institution></institution-wrap>Hsinchu, Taiwan </aff><aff id="Aff41"><label>41</label><institution-wrap><institution-id institution-id-type="GRID">grid.414686.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1797 2180</institution-id><institution>Department of Internal Medicine, </institution><institution>E-Da Hospital, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff42"><label>42</label><institution-wrap><institution-id institution-id-type="GRID">grid.411447.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0637 1806</institution-id><institution>School of Medicine, College of Medicine, </institution><institution>I-Shou University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff43"><label>43</label><institution-wrap><institution-id institution-id-type="GRID">grid.412094.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 7815</institution-id><institution>Hepatitis Research Center and Department of Internal Medicine, </institution><institution>National Taiwan University Hospital, </institution></institution-wrap>Taipei, Taiwan </aff><aff id="Aff44"><label>44</label><institution-wrap><institution-id institution-id-type="GRID">grid.260539.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2059 7017</institution-id><institution>Institute of Clinical Medicine, </institution><institution>National Yang-Ming Chiao Tung University, </institution></institution-wrap>Taipei, Taiwan </aff><aff id="Aff45"><label>45</label><institution-wrap><institution-id institution-id-type="GRID">grid.413878.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 9327</institution-id><institution>Division of Gastroenterology and Hepatology, Department of Medicine, </institution><institution>Ditmanson Medical Foundation Chiayi Christian Hospital, </institution></institution-wrap>Chiayi, Taiwan </aff><aff id="Aff46"><label>46</label>Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan </aff><aff id="Aff47"><label>47</label><institution-wrap><institution-id institution-id-type="GRID">grid.411824.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0622 7222</institution-id><institution>School of Medicine, </institution><institution>Tzuchi University, </institution></institution-wrap>Hualien, Taiwan </aff><aff id="Aff48"><label>48</label><institution-wrap><institution-id institution-id-type="GRID">grid.413804.a</institution-id><institution>Division of Hepatogastroenterology, Department of Internal Medicine, </institution><institution>Kaohsiung Chang Gung Memorial Hospital, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff49"><label>49</label><institution-wrap><institution-id institution-id-type="GRID">grid.412036.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0531 9758</institution-id><institution>School of Medicine, College of Medicine, Center of Excellence for Metabolic Associated Fatty Liver Disease, </institution><institution>National Sun Yat-Sen University, </institution></institution-wrap>Kaohsiung, Taiwan </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2023</year></pub-date><volume>17</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">432058</issue-id><fpage>550</fpage><lpage>561</lpage><history><date date-type="received"><day>28</day><month>10</month><year>2022</year></date><date date-type="accepted"><day>22</day><month>2</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>28</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-18 04:25:46.157"><day>18</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; Asian Pacific Association for the Study of the Liver 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12072_2023_Article_10506.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Large-scale real-world data of the 8-week glecaprevir/pibrentasvir (GLE/PIB) therapy for treatment-na&#239;ve patients of chronic hepatitis C virus (HCV) infection with compensated cirrhosis is scarce.</p></sec><sec><title>Methods</title><p id="Par2">The TASL HCV Registry (TACR) is an ongoing nationwide registry program that aims to set up a database and biobank of patients with chronic HCV infection in Taiwan. In this study, data were analyzed as of 31 October 2021 for treatment-na&#239;ve HCV patients with compensated cirrhosis receiving 8-week GLE/PIB therapy. Effectiveness reported as sustained virologic response at off-therapy week 12 (SVR12) and safety profiles were assessed. Patient characteristics potentially related to SVR12 were also evaluated.</p></sec><sec><title>Results</title><p id="Par3">Of the 301 patients enrolled, 275 had available SVR12 data. The SVR12 rate was 98.2% (270/275) in the modified intention-to-treat (mITT) population and 89.7% (270/301) in the ITT population. For those mITT patients with genotype 3, FibroScan&#8201;&gt;&#8201;20&#160;kPa, platelet&#8201;&lt;&#8201;150,000/&#181;l, and FibroScan&#8201;&gt;&#8201;20&#160;kPa and platelet&#8201;&lt;&#8201;150,000/&#181;l, the SVR12 rates were 100% (6/6), 100% (12/12), 98.0% (144/147), 100% (7/7), respectively. Overall, 24.9% (75/301) patients experienced adverse events (AEs). The most frequent AEs (&gt;&#8201;5%) included fatigue (9.0%) and pruritus (7.0%). Seven (2.3%) patients experienced serious AEs and two (0.7%) resulted in permanent drug discontinuation. None of them were considered as GLE/PIB-related.</p></sec><sec><title>Conclusions</title><p id="Par4">In this large-scale real-world Taiwanese cohort, 8-week GLE/PIB therapy was efficacious and well tolerated for treatment-na&#239;ve compensated cirrhosis patients. SVR12 rates were similarly high as in the clinical trials, including those with characteristics of advanced liver disease.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s12072-023-10506-z.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Compensated cirrhosis</kwd><kwd>GLE/PIB</kwd><kwd>HCV</kwd><kwd>Sustained virologic response</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004694</institution-id><institution>Kaohsiung Medical University</institution></institution-wrap></funding-source><award-id>100CM-KMU-09</award-id><award-id>KMU-TC109B05</award-id><award-id>MOST 108&#8211;2314-B-037 -066 -MY3</award-id><award-id>KMU-KI110002</award-id><principal-award-recipient><name name-style="western"><surname>Yu</surname><given-names>Ming-Lung</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100011645</institution-id><institution>Kaohsiung Medical University Chung-Ho Memorial Hospital</institution></institution-wrap></funding-source><award-id>KMUH109-9R06</award-id><award-id>KMUH-DK(C)110011</award-id><award-id>KMUH-DK(C)110004</award-id><award-id>KMUH109-9R05</award-id><principal-award-recipient><name name-style="western"><surname>Yu</surname><given-names>Ming-Lung</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Asian Pacific Association for the Study of the Liver 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par13">Hepatitis C virus (HCV) infection is an ongoing global health problem with 58 million people living with chronic HCV infection and an estimated 290,000 deaths related to HCV in 2019 according to the World Health Organization [<xref ref-type="bibr" rid="CR1">1</xref>]. In Taiwan, the estimated prevalence of anti-HCV seropositivity was around 3&#8211;4% among the general population with an estimated 40,000 of them living with active viremic infection [<xref ref-type="bibr" rid="CR2">2</xref>]. HCV has been a leading cause of&#160;cirrhosis, end-stage liver disease, and liver-related deaths worldwide [<xref ref-type="bibr" rid="CR3">3</xref>]. Extrahepatic manifestations in multiple systems including but not limited to renal (membranoproliferative vasculitis), neurologic (peripheral neuropathies), rheumatologic (polyarthritis), immune (B-cell lymphoma and cryoglobulinemic vasculitis) and cutaneous organs (purpura and necrotizing vasculitis) can also occur in up to 70% of patients with HCV infection [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. These hepatic and extra-hepatic manifestations have contributed to the huge burden of disease that negatively impacts patient well-being and quality of life. Treatment and cure of HCV not only can prevent and even reverse both the hepatic and extra-hepatic morbidity and mortality in the individual-level but also can reduce the reservoir of those infected with HCV and thus halt HCV transmission to others in the population-level [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par14">The availability of highly effective interferon-free all-oral direct-acting antivirals (DAAs) has completely revolutionized the treatments for HCV and has marked a new era in the treatment of HCV [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. This change in HCV treatment landscape also spurred the World Health Organization to make a call for the elimination of HCV as a public health threat in 2016 and subsequently laid out a roadmap to achieve this goal by the year 2030 [<xref ref-type="bibr" rid="CR8">8</xref>]. Taiwan has accelerated its efforts to eliminate HCV since 2018 by committing to achieve the World Health Organization's 2030 goal of treating 80% of eligible patients by 2025 [<xref ref-type="bibr" rid="CR2">2</xref>]. The introduction of pangenotypic DAAs can help simplify HCV treatment pathways and decentralize testing at the primary care level and these regimens have been recommended by the World Health Organization for all eligible patients with chronic HCV infection [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par15">Of the two first-line pangenotypic DAAs, sofosbuvir/velpatasvir is recommended for a duration of 12&#160;weeks for HCV patients with or without decompensated cirrhosis, with the addition of ribavirin recommended in the presence of decompensated cirrhosis and glecaprevir/pibrentasvir (GLE/PIB) is recommended for a duration of 8, 12, or 16&#160;weeks for HCV patients without liver decompensation [<xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR13">13</xref>]. Short-duration therapy for HCV may help reduce the burden on health care resources, overcome elimination barriers, increase treatment adherence and allow more patients to be treated [<xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>]. GLE/PIB, a ribavirin-free, fixed-dose, once-daily, all-oral combination pangenotypic DAA regimen, is the only DAA regimen that has been approved for a short treatment duration of 8&#160;weeks for patients with HCV of all genotypes and without cirrhosis [<xref ref-type="bibr" rid="CR17">17</xref>]. For patients with compensated cirrhosis, the phase 3 EXPEDITION-8 trial demonstrated that the 8-week GLE/PIB regimen had a high SVR12 rate of 99.7% for treatment-na&#239;ve HCV patients with compensated cirrhosis and this 8-week regimen was subsequently approved by the US Food and Drug Administration (FDA) in September 2019 and by the Taiwan FDA in April 2020 [<xref ref-type="bibr" rid="CR18">18</xref>]. A handful of real-world reports also showed high effectiveness and safety profiles of the 8-week GLE/PIB regimen in small-scale treatment-na&#239;ve patients with HCV and compensated cirrhosis [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#8211;<xref ref-type="bibr" rid="CR25">25</xref>]. However, large-scale real-world data on this topic are scarce, especially in the Asian population. In the present study, we reported the real-world effectiveness and safety of the 8-week GLE/PIB regimen in treatment-na&#239;ve Taiwanese patients with HCV and compensated cirrhosis using the nationwide data from Taiwan Association for the Study of the Liver (TASL) HCV Registry&#160;(TACR) program [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Patients and study design</title><p id="Par16">The TACR is an ongoing non-interventional, observational nationwide registry program organized and supervised by TASL, which aims to set up a database and biobank of HCV patients who receive all-oral DAA therapy in Taiwan. By July 2022, 53 study sites, including 21 medical centres, 27 regional hospitals and five primary clinics from all around Taiwan, were participating in the program. Enrolling criteria for this registry program include HCV patients aged&#8201;&#8805;&#8201;20&#160;years with detectable HCV RNA and received all-oral DAA-containing regimens. The program protocol was approved by the Institutional Review Board at the individual study site, which conformed to the guidelines of the International Conference on Harmonization for Good Clinical Practice. Informed consent was obtained from all patients before being enrolled. All patient records were reviewed, and data were extracted and validated at each participating site using a standardized case report form and a unified coding dictionary for the pre-defined patient (including demographics, laboratory profiles, HCV treatment data, comorbidities and cirrhotic status) and virologic characteristics (including HCV viral loads, genotypes and treatment outcomes) before and after antiviral treatment. The choice of DAA regimen was granted at the discretion of the treating physician based on the labels approved by the Taiwan FDA, which were in compliance with the local and major international guidelines for HCV infection, [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>] and the regulations of the Ministry of Health and Welfare in Taiwan. The diagnosis of cirrhosis was based on any of the following modalities: liver histology; transient elastography (FibroScan<sup>&#174;</sup>; Echosens, Paris, France) (&gt;&#8201;12&#160;kPa); acoustic radiation force impulse (&gt;&#8201;1.98&#160;m/s); fibrosis-4 (FIB-4) index (&gt;&#8201;6.5); or the presence of clinical, radiological, endoscopic, or laboratory evidence of cirrhosis and/or portal hypertension. Inactive hepatocellular carcinoma (HCC) was defined as those who were subjected to curative therapies including surgical resection, local ablation or liver transplantation and without imaging evidence of viable HCC within 3&#160;months prior to the commence of DAA prescription. Chronic kidney disease (CKD) was defined as a decreased estimated glomerular filtration rate (eGFR,&#8201;&lt;&#8201;60&#160;ml/min/1.73 m<sup>2</sup>) or kidney function impairment (<italic toggle="yes">e.g.</italic>, presence of proteinura) for more than 3&#160;months.</p></sec><sec id="Sec4"><title>Assessments and outcomes</title><p id="Par17">For this study, data were analyzed as of 31 October 2021 for treatment-na&#239;ve patients with HCV and compensated cirrhosis who received 8&#160;weeks of GLE/PIB. Effectiveness was reported as sustained virologic response at post-treatment week 12 (SVR12) which was defined as undetectable HCV RNA level (&lt;&#8201;lower limit of quantification) at off-therapy week 12. The intention-to-treat (ITT) population included all patients who received 1 or more doses of GLE/PIB and the modified ITT (mITT) population excluded patients with nonvirologic failure (ie, patients who were lost to follow-up or discontinued treatment without experiencing virologic failure). SVR12 rates were assessed in the ITT and the mITT populations. SVR12 rates were also evaluated in prespecified patient subgroups categorized according to baseline characteristics including age, gender, HCV genotype, and comorbidities such as HBV or HIV co-infection, HCC, cardiovascular disease, cerebrovascular accident, diabetes mellitus, hypertension, hyperlipidemia, people who injected drugs (PWID), and CKD and in the following subgroups of interest including patients with HCV genotype 3, platelet count&#8201;&lt;&#8201;150,000/&#181;l, FibroScan&#8201;&gt;&#8201;20&#160;kPa, or both platelet count&#8201;&lt;&#8201;150,000/&#181;l and FibroScan&#8201;&gt;&#8201;20&#160;kPa. Drug adherence, defined as the percentage of actual dosage being taken divided by the anticipated DAA dosage throughout the treatment course in each subject, was evaluated. Safety outcomes expressed as the percentages of patients with adverse events (AEs) was assessed in the ITT population. Healthcare resource utilization (HCRU) was defined as the number of clinic visits from GLE/PIB initiation to the SVR12 survey visit.</p></sec><sec id="Sec5"><title>Statistical analyses</title><p id="Par18">Descriptive statistics including mean (&#177;&#8201;standard deviation, SD), number or frequency (percentage) were used to summarize baseline demographics, clinical characteristics, drug adherence, AE and HCRU. The overall and stratified SVR12 rates were shown in numbers and percentages with 95% confidence interval (CI). Frequencies were compared between groups using the &#967;<sup>2</sup> test with the Yates correction or Fisher&#8217;s exact test. Group means were compared using analysis of variance and Student&#8217;s <italic toggle="yes">t</italic>-test or the nonparametric Mann&#8211;Whitney U test when appropriate. Stepwise logistic regression analysis was performed to determine factors associated with treatment failure by analyzing the covariates with a <italic toggle="yes">p</italic> value&#8201;&lt;&#8201;0.1 in the univariate analysis. All statistical analyses were performed using the SPSS 12.0 statistical package (SPSS, Chicago, IL, USA). A two-tailed <italic toggle="yes">p</italic>-value of&#8201;&lt;&#8201;0.05 was considered significant.</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Patient characteristics</title><p id="Par19">As shown in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>, there were a total of 8,305 treatment-na&#239;ve HCV patients with compensated cirrhosis in the TACR platform as of 31 October 2021. GLE/PIB was prescribed for 806 patients and 301 of them received the 8-week regimen for at least 1 dose (ITT). SVR12 data were not available for 26 patients and finally 275 patients were analyzed in the mITT population. As shown in Table <xref rid="Tab1" ref-type="table">1</xref>, among the 301 patients of the ITT population, the average age was 63.0&#8201;&#177;&#8201;13.2&#160;years, 162 or 53.8% patients were male, 142 or 47.2% patients were older than 65&#160;years, the most common genotype was genotype 2 (166 or 55.1%) followed by genotypes 1a/1b (88 or 29.2%), genotypes 4/5/6 (21 or 7%), mixed/unclassified (18 or 6%) and genotype 3 (8 or 2.7%). The average HCV RNA was 5.8&#8201;&#177;&#8201;1.2 log<sub>10</sub> IU/mL with 55 or 18.3% of patients had an HCV RNA level of&#8201;&gt;&#8201;6,000,000&#160;IU/ml. The average alanine aminotransferase (ALT) was 77.9&#8201;&#177;&#8201;66.9&#160;IU/L, aspartate aminotransferase (AST) 76.1&#8201;&#177;&#8201;67.3&#160;IU/L, platelet count 154.5&#8201;&#177;&#8201;78.7 10<sup>3</sup> U/L, albumin 4.1&#8201;&#177;&#8201;0.4&#160;g/dL, total bilirubin 0.9&#8201;&#177;&#8201;0.4&#160;mg/dL, creatinine 1.0&#8201;&#177;&#8201;0.7&#160;mg/dL, and FIB-4 score 5.0&#8201;&#177;&#8201;4.6. HBV coinfection was noted in 19 or 6.3% of patients and HIV coinfection in 7 or 2.3% of patients. Twenty five or 8.3% had HCC (11 or 3.7% of them had active HCC) and 18 or 6% of patients were people who inject drugs (PWID). Patients with Child&#8211;Pugh score of A5 and A6 were 251 (83.4%) and 41 (13.6%), respectively. The remaining 9 (3%) patients had no complete parameters for Child&#8211;Pugh classification. The most common comorbidities included hypertension (124 or 41.2% patients), CKD (82 or 27.2% patients), diabetes mellitus (73 or 24.3% patients), hyperlipidemia (39 or 13.0% patients) and cardiovascular disease (30 or 10.0% patients). The values or rates of baseline characteristics and clinical features of the mITT population were numerically comparable to those of the ITT population (Supplementary Table 1).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Study flow diagram. <italic toggle="yes">DAA</italic> direct-acting antiviral; <italic toggle="yes">GLE</italic> glecaprevir; <italic toggle="yes">ITT</italic> intention-to-treat; <italic toggle="yes">mITT</italic> modified intention-to-treat; <italic toggle="yes">PIB</italic> pibrentasvir</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="12072_2023_10506_Fig1_HTML.jpg"/></fig><table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics and clinical features (ITT) (n&#8201;=&#8201;301)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Characteristics</th><th align="left" colspan="1" rowspan="1">Mean&#8201;&#177;&#8201;SD or N (%)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="left" colspan="1" rowspan="1">63.0&#8201;&#177;&#8201;13.2</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Age&#8201;&#8805;&#8201;65 y, n (%)</td><td align="left" colspan="1" rowspan="1">142 (47.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Age&#8201;&#8805;&#8201;80 y, n (%)</td><td align="left" colspan="1" rowspan="1">30 (10.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Male, n (%)</td><td align="left" colspan="1" rowspan="1">162 (53.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">HCV RNA, log<sub>10</sub> IU/mL</td><td align="left" colspan="1" rowspan="1">5.8&#8201;&#177;&#8201;1.2</td></tr><tr><td align="left" colspan="1" rowspan="1">HCV RNA&#8201;&gt;&#8201;6,000,000&#160;IU/ml, n (%)</td><td align="left" colspan="1" rowspan="1">55 (18.3)</td></tr><tr><td align="left" colspan="2" rowspan="1">HCV genotype</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;1a/1b, n (%)</td><td align="left" colspan="1" rowspan="1">88 (29.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;2, n (%)</td><td align="left" colspan="1" rowspan="1">166 (55.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;3, n (%)</td><td align="left" colspan="1" rowspan="1">8 (2.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;4/5/6, n (%)</td><td align="left" colspan="1" rowspan="1">21 (7.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mixed/ unclassified, n (%)</td><td align="left" colspan="1" rowspan="1">18 (6.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">AST, IU/L</td><td align="left" colspan="1" rowspan="1">76.1&#8201;&#177;&#8201;67.3</td></tr><tr><td align="left" colspan="1" rowspan="1">ALT, IU/L</td><td align="left" colspan="1" rowspan="1">77.9&#8201;&#177;&#8201;66.9</td></tr><tr><td align="left" colspan="1" rowspan="1">Platelet count,&#8201;&#215;&#8201;10<sup>3</sup> U/L</td><td align="left" colspan="1" rowspan="1">154.5&#8201;&#177;&#8201;78.7</td></tr><tr><td align="left" colspan="1" rowspan="1">Albumin, g/dL</td><td align="left" colspan="1" rowspan="1">4.1&#8201;&#177;&#8201;0.4</td></tr><tr><td align="left" colspan="1" rowspan="1">Total bilirubin, mg/dL</td><td align="left" colspan="1" rowspan="1">0.9&#8201;&#177;&#8201;0.4</td></tr><tr><td align="left" colspan="1" rowspan="1">Creatinine, mg/dL<sup>a</sup></td><td align="left" colspan="1" rowspan="1">1.0&#8201;&#177;&#8201;0.7</td></tr><tr><td align="left" colspan="1" rowspan="1">FIB-4</td><td align="left" colspan="1" rowspan="1">5.0&#8201;&#177;&#8201;4.6</td></tr><tr><td align="left" colspan="1" rowspan="1">HBV coinfection, n (%)</td><td align="left" colspan="1" rowspan="1">19 (6.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">HIV coinfection, n (%)</td><td align="left" colspan="1" rowspan="1">7 (2.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hepatocellular carcinoma, n (%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No HCC</td><td align="left" colspan="1" rowspan="1">276 (91.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Inactive</td><td align="left" colspan="1" rowspan="1">14 (4.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Active</td><td align="left" colspan="1" rowspan="1">11 (3.7)</td></tr><tr><td align="left" colspan="2" rowspan="1">Child&#8211;Pugh, n (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;A5</td><td align="left" colspan="1" rowspan="1">251 (83.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;A6</td><td align="left" colspan="1" rowspan="1">41 (13.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Data not available</td><td align="left" colspan="1" rowspan="1">9 (3.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">PWID, n (%)</td><td align="left" colspan="1" rowspan="1">18 (6.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Comorbidities</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Cardiovascular disease</td><td align="left" colspan="1" rowspan="1">30 (10.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Diabetes mellitus</td><td align="left" colspan="1" rowspan="1">73 (24.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hypertension</td><td align="left" colspan="1" rowspan="1">124 (41.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hyperlipidemia</td><td align="left" colspan="1" rowspan="1">39 (13.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Chronic kidney disease<sup>b</sup></td><td align="left" colspan="1" rowspan="1">82 (27.2)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ALT</italic> alanine aminotransferase; <italic toggle="yes">AST</italic> aspartate aminotransferase; <italic toggle="yes">CKD</italic> chronic kidney disease; <italic toggle="yes">HBV</italic> hepatitis B virus; <italic toggle="yes">HCV</italic> hepatitis C virus; <italic toggle="yes">HCC</italic> hepatocellular carcinoma; <italic toggle="yes">HIV</italic> human immunodeficiency virus; <italic toggle="yes">ITT</italic> intention-to-treat; <italic toggle="yes">PWID</italic> people who inject drugs; <italic toggle="yes">SD</italic> standard deviation</p><p><sup>a</sup>Excluded dialysis patients (n&#8201;=&#8201;36)</p><p><sup>b</sup>CKD: Dialysis or BL CKD stage3-5 or stage 1&#8211;2/proteinuria&#8201;=&#8201;&#8201;+&#8201;</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec8"><title>Treatment responses</title><p id="Par20">The overall SVR12 rate was 98.2% (270/275) in the mITT population and 89.7% (270/301) in the ITT population. Of the 5 patients with virologic failure, four were non-responders, one was a relapser, and none had a virologic breakthrough. The characteristics of the 5 patients with virologic failure were described in detail in Supplementary Table 2. For the 26 patients with non-virologic failure, 18 were lost to follow-up, three had no available data and five died. The reasons of the five deaths included one from lung cancer with pneumonia and sepsis, two from sepsis, one from respiratory failure and one with unknown reasons (Table <xref rid="Tab2" ref-type="table">2</xref>). The SVR rates for genotypes 1, 2, 3, 4/5/6, and mixed/unclassified were 97.5% (78/80), 98.1% (154/157), 100% (6/6), 100% (17/17), 100% (15/15), respectively in the mITT population (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). For patient subgroups of interest including FibroScan&#8201;&gt;&#8201;20&#160;kPa, platelet count&#8201;&lt;&#8201;150,000/&#181;l, both FibroScan&#8201;&gt;&#8201;20&#160;kPa and platelet count&#8201;&lt;&#8201;150,000/&#181;l, APRI&#8201;&gt;&#8201;1.09, FIB4&#8201;&gt;&#8201;3.25, active HCC and albumin&#8201;&lt;&#8201;3.5&#160;g/dL, the SVR rates were 100% (12/12), 98.0% (144/147), 100% (7/7), 100% (125/125), 98% (145/148), 100% (9/9) and 95.8% (23/24), respectively (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). The Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref> demonstrated the SVR12 rates of patients stratified by specific comorbidities including CKD (73/77, 94.8%), diabetes mellitus (66/68, 97.1%), cardiovascular disease (27/28, 96.4%), cerebrovascular accident (7/7, 100%), hypertension (114/117, 97.4%), and hyperlipidemia (35/35, 100%).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Overall SVR12 and reasons for non-SVR</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">All patients (N&#8201;=&#8201;301)</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">SVR 12</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;ITT, n/N (%)</td><td align="left" colspan="1" rowspan="1">270/301 (89.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;mITT, n/N (%)</td><td align="left" colspan="1" rowspan="1">270/275 (98.2)</td></tr><tr><td align="left" colspan="2" rowspan="1">Reason for non-SVR 12 (n&#8201;=&#8201;31)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Virologic failure, n</td><td align="left" colspan="1" rowspan="1">5 (1.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Breakthrough, n</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Relapse, n</td><td align="left" colspan="1" rowspan="1">1 (0.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;non-response, n</td><td align="left" colspan="1" rowspan="1">4 (1.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Non-virologic failure, n</td><td align="left" colspan="1" rowspan="1">26 (8.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Lost to follow-up, n</td><td align="left" colspan="1" rowspan="1">18 (6.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Without available data, n</td><td align="left" colspan="1" rowspan="1">3 (1.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#160;Death, n</td><td align="left" colspan="1" rowspan="1">5<sup>a</sup> (1.6)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ITT</italic> intention-to-treat; <italic toggle="yes">mITT</italic> modified intention-to-treat</p><p><sup>a</sup>5 pts died:1 pt died from lung cancer with pneumonia; 1 pt died from respiratory failure; 2 pts died from sepsis;1pt died from unknown reasons</p></table-wrap-foot></table-wrap><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Rate of SVR12 stratified by different genotypes. <italic toggle="yes">mITT</italic> modified intention-to-treat</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="12072_2023_10506_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Rate of SVR12 stratified by patient subgroups of interest. <italic toggle="yes">mITT</italic> modified intention-to-treat</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="12072_2023_10506_Fig3_HTML.jpg"/></fig><fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Rate of SVR12 stratified by patient subgroups of co-morbidities. <italic toggle="yes">mITT</italic> modified intention-to-treat; <italic toggle="yes">CAD</italic> coronary artery disease; <italic toggle="yes">CKD</italic> chronic kidney disease; <italic toggle="yes">CVA</italic> cerebrovascular accident; <italic toggle="yes">DM</italic> diabetes mellitus; HLD, hyperlipidemia</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="12072_2023_10506_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec9"><title>Subgroup analysis for SVR12</title><p id="Par21">As shown in Supplementary Table 3, the SVR12 rates in the mITT population were all&#8201;&gt;&#8201;95% when stratified by baseline patient characteristics including age, gender, HBV or HIV coinfection, history of HCC, HCV genotype, platelet count, albumin, PWID and fibrosis degree as depicted by Fibroscan, APRI or FIB-4 index except for HCV RNA&#8201;&gt;&#8201;6,000,000&#160;IU/ml (SVR12 rate 92.2%, 95% CI 81.5&#8211;96.9) and the presence of CKD (SVR12 rate 94.8%, 95% CI 87.4&#8211;98.0).</p><p id="Par22">Univariate and subsequent multivariate logistic regression analyses showed that factors independently associated with treatment failure included baseline HCV RNA level&#8201;&gt;&#8201;6,000,000&#160;IU/ml (adjusted odds ratio [OR]: 20.58, 95% CI 1.98&#8211;214.10, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01), and drug adherence&#8201;&lt;&#8201;80% (adjusted OR 42.66, 95% CI 1.54&#8211;1185.30, <italic toggle="yes">p</italic>&#8201;=&#8201;0.03). Age, gender, HCV genotype, or comorbidities such as HBV or HIV co-infection, HCC, PWID, and CKD were not associated with treatment outcomes (Table <xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Univariate and multivariate logistic regression analysis of factors associated with treatment failure (mITT)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Predictor</th><th align="left" colspan="1" rowspan="1">DAA failure, n/N (%)</th><th align="left" colspan="1" rowspan="1">Unadjusted OR (95% CI)</th><th align="left" colspan="1" rowspan="1">p value</th><th align="left" colspan="1" rowspan="1">Adjusted OR (95% CI)</th><th align="left" colspan="1" rowspan="1">p value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&lt;&#8201;65</td><td align="left" colspan="1" rowspan="1">3/145 (2.1)</td><td align="left" colspan="1" rowspan="1">Ref</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805;&#8201;65</td><td align="left" colspan="1" rowspan="1">2/130 (1.5)</td><td align="left" colspan="1" rowspan="1">0.73 (0.12&#8211;4.50)</td><td char="." align="char" colspan="1" rowspan="1">0.74</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Gender</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Female</td><td align="left" colspan="1" rowspan="1">2/129 (1.6)</td><td align="left" colspan="1" rowspan="1">Ref</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Male</td><td align="left" colspan="1" rowspan="1">3/146 (2.1)</td><td align="left" colspan="1" rowspan="1">1.33 (0.22&#8211;8.10)</td><td char="." align="char" colspan="1" rowspan="1">0.76</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">HBV coinfection</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">5/258 (1.9)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">0/17 (0.0)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">HIV coinfection</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">5/269 (1.9)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">0/6 (0.0)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">History of HCC</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">5/255 (2.0)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Active HCC</td><td align="left" colspan="1" rowspan="1">0/11 (0.0)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Inactive HCC</td><td align="left" colspan="1" rowspan="1">0/9 (0.0)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">HCV RNA, log</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8201;&#8804;&#8201;6,000,000&#160;IU/ml</td><td align="left" colspan="1" rowspan="1">1/224 (0.5)</td><td align="left" colspan="1" rowspan="1">Ref</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Ref</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&gt;&#8201;6,000,000&#160;IU/ml</td><td align="left" colspan="1" rowspan="1">4/51 (7.8)</td><td align="left" colspan="1" rowspan="1">18.98 (2.07&#8211;173.66)</td><td char="." align="char" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">20.58 (1.98&#8211;214.10)</td><td char="." align="char" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">HCV genotype</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Non-GT3</td><td align="left" colspan="1" rowspan="1">5/269 (1.9)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;GT3</td><td align="left" colspan="1" rowspan="1">0/6 (0.0)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">PWID</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">5/262 (1.9)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">0/13 (0.0)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">CKD</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">1/198 (0.5)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">4/77 (5.2)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Adherence</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805;&#8201;80%</td><td align="left" colspan="1" rowspan="1">4/272 (1.5)</td><td align="left" colspan="1" rowspan="1">Ref</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Ref</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&lt;&#8201;80%</td><td align="left" colspan="1" rowspan="1">1/3 (33.3)</td><td align="left" colspan="1" rowspan="1">33.50 (2.50&#8211;449.03)</td><td char="." align="char" colspan="1" rowspan="1">0.01</td><td align="left" colspan="1" rowspan="1">42.66 (1.54&#8211;1185.30)</td><td char="." align="char" colspan="1" rowspan="1">0.03</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">CKD</italic> chronic kidney disease; <italic toggle="yes">GT</italic> genotype; <italic toggle="yes">HBV</italic> hepatitis B virus; <italic toggle="yes">HCC</italic> hepatocellular carcinoma; <italic toggle="yes">HIV</italic> human immunodeficiency virus; <italic toggle="yes">mITT</italic> modified intention-to-treat; <italic toggle="yes">PWID</italic> people who inject drugs</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Changes of laboratory profiles</title><p id="Par23">Table <xref rid="Tab4" ref-type="table">4</xref> showed the changes of laboratory profiles at week 4, end of treatment and 12&#160;weeks off-therapy compared to their counterparts at the baseline. The laboratory profiles that changed at week 4 included total bilirubin (from 0.9&#8201;&#177;&#8201;0.4 to 1.0&#8201;&#177;&#8201;0.7&#160;mg/dL, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01), ALT (from 77.9&#8201;&#177;&#8201;66.9 to 25.2&#8201;&#177;&#8201;20.3&#160;IU/L, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01), and AST (from 76.1&#8201;&#177;&#8201;67.3 to 32.5&#8201;&#177;&#8201;33.4&#160;IU/L, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). The laboratory profiles that changed at end of treatment included INR (from 1.1&#8201;&#177;&#8201;0.1 to 1.03&#8201;&#177;&#8201;0.07&#160;s, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01), total bilirubin (from 0.9&#8201;&#177;&#8201;0.4 to 1.0&#8201;&#177;&#8201;0.6&#160;mg/dL, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01), albumin (from 4.1&#8201;&#177;&#8201;0.4 to 4.2&#8201;&#177;&#8201;0.4&#160;g/dL, <italic toggle="yes">p</italic>&#8201;=&#8201;0.03), ALT (from 77.9&#8201;&#177;&#8201;66.9 to 23.9&#8201;&#177;&#8201;18.56&#160;IU/L, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01), and AST (from 76.1&#8201;&#177;&#8201;67.3 to 29.4&#8201;&#177;&#8201;17.6&#160;IU/L, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). The laboratory profiles that changed 12&#160;weeks off-therapy included INR (from 1.1&#8201;&#177;&#8201;0.1 to 1.03&#8201;&#177;&#8201;0.08&#160;s, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01), total bilirubin (from 0.9&#8201;&#177;&#8201;0.4 to 0.8&#8201;&#177;&#8201;0.5&#160;mg/dL, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01), albumin (from 4.1&#8201;&#177;&#8201;0.4 to 4.2&#8201;&#177;&#8201;0.4&#160;g/dL, <italic toggle="yes">p</italic>&#8201;=&#8201;0.03), ALT (from 77.9&#8201;&#177;&#8201;66.9 to 24.1&#8201;&#177;&#8201;16.9&#160;IU/L, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01), and AST (from 76.1&#8201;&#177;&#8201;67.3 to 29.3&#8201;&#177;&#8201;15.9&#160;IU/L, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). Notably, the serum creatinine levels did not significantly change throughout the treatment course.<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Laboratory findings before, during, and after treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Characteristics</th><th align="left" colspan="1" rowspan="1">Baseline</th><th align="left" colspan="1" rowspan="1">PTW4</th><th align="left" colspan="1" rowspan="1">Paired p value (vs baseline)</th><th align="left" colspan="1" rowspan="1">EOT</th><th align="left" colspan="1" rowspan="1">Paired p value (vs baseline)</th><th align="left" colspan="1" rowspan="1">SVR12</th><th align="left" colspan="1" rowspan="1">Paired p value (vs baseline)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">INR (s)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mean (SD)</td><td align="left" colspan="1" rowspan="1">1.1&#8201;&#177;&#8201;0.1</td><td align="left" colspan="1" rowspan="1">1.1&#8201;&#177;&#8201;0.1</td><td char="." align="char" colspan="1" rowspan="1">0.23</td><td align="left" colspan="1" rowspan="1">1.03&#8201;&#177;&#8201;0.07</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.01</td><td align="left" colspan="1" rowspan="1">1.03&#8201;&#177;&#8201;0.08</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Median (Q1&#8211;Q3)</td><td align="left" colspan="1" rowspan="1">1.0 (1.0&#8211;1.1)</td><td align="left" colspan="1" rowspan="1">1.0 (1.0&#8211;1.1)</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.0 (1.0&#8211;1.1)</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.0 (1.0&#8211;1.1)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Min&#8211;Max</td><td align="left" colspan="1" rowspan="1">0.8&#8211;1.6</td><td align="left" colspan="1" rowspan="1">0.9&#8211;1.3</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.9&#8211;1.4</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.8&#8211;1.7</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">241</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">120</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">35</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Total Bilirubin (mg/dL)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mean (SD)</td><td align="left" colspan="1" rowspan="1">0.9&#8201;&#177;&#8201;0.4</td><td align="left" colspan="1" rowspan="1">1.0&#8201;&#177;&#8201;0.7</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.01</td><td align="left" colspan="1" rowspan="1">1.0&#8201;&#177;&#8201;0.6</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.01</td><td align="left" colspan="1" rowspan="1">0.8&#8201;&#177;&#8201;0.5</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Median (Q1&#8211;Q3)</td><td align="left" colspan="1" rowspan="1">0.8 (0.6&#8211;1.1)</td><td align="left" colspan="1" rowspan="1">0.9 (0.6&#8211;1.2)</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.9 (0.6&#8211;1.2)</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.7 (0.5&#8211;1.0)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Min&#8211;Max</td><td align="left" colspan="1" rowspan="1">0.2&#8211;2.7</td><td align="left" colspan="1" rowspan="1">0.1&#8211;5.7</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.1&#8211;4.5</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.2&#8211;4.9</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">17</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">20</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">32</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Albumin (g/dL)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mean (SD)</td><td align="left" colspan="1" rowspan="1">4.1&#8201;&#177;&#8201;0.4</td><td align="left" colspan="1" rowspan="1">4.0&#8201;&#177;&#8201;0.4</td><td char="." align="char" colspan="1" rowspan="1">0.34</td><td align="left" colspan="1" rowspan="1">4.2&#8201;&#177;&#8201;0.4</td><td char="." align="char" colspan="1" rowspan="1">0.03</td><td align="left" colspan="1" rowspan="1">4.2&#8201;&#177;&#8201;0.4</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Median (Q1&#8211;Q3)</td><td align="left" colspan="1" rowspan="1">4.1 (3.8&#8211;4.4)</td><td align="left" colspan="1" rowspan="1">4.1 (3.8&#8211;4.3)</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">4.2 (3.9&#8211;4.5)</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">4.3 (4&#8211;4.5)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Min&#8211;Max</td><td align="left" colspan="1" rowspan="1">2.8&#8211;5.0</td><td align="left" colspan="1" rowspan="1">3.0&#8211;5.0</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">3.0&#8211;5.1</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2.8&#8211;5.3</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">224</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">111</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">36</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">ALT (IU/L)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mean (SD)</td><td align="left" colspan="1" rowspan="1">77.9&#8201;&#177;&#8201;66.9</td><td align="left" colspan="1" rowspan="1">25.2&#8201;&#177;&#8201;20.3</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.01</td><td align="left" colspan="1" rowspan="1">23.9&#8201;&#177;&#8201;18.56</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.01</td><td align="left" colspan="1" rowspan="1">24.1&#8201;&#177;&#8201;16.9</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Median (Q1&#8211;Q3)</td><td align="left" colspan="1" rowspan="1">56.0 (27&#8211;110)</td><td align="left" colspan="1" rowspan="1">20 (14&#8211;30)</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">19 (14&#8211;27)</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">19 (14&#8211;27)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Min&#8211;Max</td><td align="left" colspan="1" rowspan="1">8&#8211;326</td><td align="left" colspan="1" rowspan="1">7&#8211;189</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">5&#8211;177</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">4.3&#8211;144</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">12</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">19</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">30</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">AST (IU/L)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mean (SD)</td><td align="left" colspan="1" rowspan="1">76.1&#8201;&#177;&#8201;67.3</td><td align="left" colspan="1" rowspan="1">32.5&#8201;&#177;&#8201;33.4</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.01</td><td align="left" colspan="1" rowspan="1">29.4&#8201;&#177;&#8201;17.6</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.01</td><td align="left" colspan="1" rowspan="1">29.3&#8201;&#177;&#8201;15.9</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Median (Q1&#8211;Q3)</td><td align="left" colspan="1" rowspan="1">57.0 (30&#8211;97.5)</td><td align="left" colspan="1" rowspan="1">25 (20.3&#8211;35)</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">25 (20&#8211;33)</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">25 (20&#8211;34)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Min&#8211;Max</td><td align="left" colspan="1" rowspan="1">8&#8211;505</td><td align="left" colspan="1" rowspan="1">6&#8211;495</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">8&#8211;150</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">11&#8211;132</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">13</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">19</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">30</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Creatinine (mg/dL)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mean (SD)</td><td align="left" colspan="1" rowspan="1">1.8&#8201;&#177;&#8201;2.5</td><td align="left" colspan="1" rowspan="1">1.9&#8201;&#177;&#8201;2.6</td><td char="." align="char" colspan="1" rowspan="1">0.59</td><td align="left" colspan="1" rowspan="1">1.8&#8201;&#177;&#8201;2.4</td><td char="." align="char" colspan="1" rowspan="1">0.48</td><td align="left" colspan="1" rowspan="1">1.9&#8201;&#177;&#8201;2.5</td><td char="." align="char" colspan="1" rowspan="1">0.61</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Median (Q1&#8211;Q3)</td><td align="left" colspan="1" rowspan="1">0.9 (0.7&#8211;1.2)</td><td align="left" colspan="1" rowspan="1">1.0 (0.8&#8211;1.4)</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.9 (0.7&#8211;1.3)</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.9 (0.8&#8211;1.3)</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Min&#8211;Max</td><td align="left" colspan="1" rowspan="1">0.4&#8211;14.6</td><td align="left" colspan="1" rowspan="1">0.4&#8211;14.6</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.4&#8211;12.8</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.5&#8211;14.5</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">179</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">72</td><td char="." align="char" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">37</td><td char="." align="char" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">EOT</italic> end of treatment; <italic toggle="yes">ITT</italic> intention-to-treat; <italic toggle="yes">PTW4</italic> post-treatment at week 4; <italic toggle="yes">SVR12</italic> sustained virologic response at off-therapy week 12</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Safety</title><p id="Par24">Of the 301 patients, 75 or 24.9% reported at least one AE as demonstrated in Table <xref rid="Tab5" ref-type="table">5</xref>. Of them, 7 or 2.3% patients had serious adverse events but none was considered DAA-related. Drug discontinuation due to AEs was observed in four patients, two temporarily due to acute pancreatitis and hospitalization for unknown reasons, respectively and two permanently due to patient noncompliance and hyperbilirubinemia, respectively. Common AEs that occurred in&#8201;&#8805;&#8201;1% of patients included fatigue in 27 (9.0%), pruritus in 21 (7.0%), insomnia in 5 (1.7%), skin rash in 4 (1.3%), and headache in 3 (1.0%) patients.<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Safety summary (DAA, direct-acting antiviral)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Event, n (%)</th><th align="left" colspan="1" rowspan="1">All patients (n&#8201;=&#8201;301)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Any adverse event</td><td align="left" colspan="1" rowspan="1">75 (24.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Serious adverse event</td><td align="left" colspan="1" rowspan="1">7 (2.3)<sup>a</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">DAA-related serious adverse event</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td></tr><tr><td align="left" colspan="2" rowspan="1">Discontinuation due to adverse event</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Temporary</td><td align="left" colspan="1" rowspan="1">2 (0.7)<sup>b</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Permanent</td><td align="left" colspan="1" rowspan="1">2 (0.7)<sup>c</sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Adverse event occurring in&#8201;&#8805;&#8201;1% of patients</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Fatigue</td><td align="left" colspan="1" rowspan="1">27 (9.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Headache</td><td align="left" colspan="1" rowspan="1">3 (1.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Pruritus</td><td align="left" colspan="1" rowspan="1">21 (7.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Rash</td><td align="left" colspan="1" rowspan="1">4 (1.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Insomnia</td><td align="left" colspan="1" rowspan="1">5 (1.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Others</td><td align="left" colspan="1" rowspan="1">12 (4.0)<sup>d</sup></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>5 pts died: 1 died from lung cancer and pneumonia, 1 died from respiratory failure, 2 died from sepsis, and 1 died from unknown reasons; 1 pt had pancreatitis;1 pt admitted to another hospital</p><p><sup>b</sup>1 pt had pancreatitis;1 pt admitted to another hospital</p><p><sup>c</sup>1 pt discontinued by pt himself; 1 pt discontinued due to elevated total bilirubin</p><p><sup>d</sup>2 pts: depression; 1 pt: bloating;1 pt: poor appetite; 6 pts: dizziness; 2pts: sick</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Drug adherence</title><p id="Par25">Of all the 301 patients, drug adherence for 80&#8211;100%, &lt;80%,&#160;60&#8211;80%, 40&#8211;60%, 20&#8211;40% and&#8201;&lt;&#8201;20% was 285 (94.7%), 16 (5.3%), 4 (1.3%), 6 (2.0%), 3 (1.0%), and 3 (1.0%), respectively (Supplementary Table 4).</p></sec><sec id="Sec13"><title>Healthcare resource utilization</title><p id="Par26">The healthcare resource utilization (number of clinic visits from DAA initiation to SVR12) for the 301 ITT population was 5.3&#8201;&#177;&#8201;1.3 as shown in Supplementary Table 5.</p></sec></sec><sec id="Sec14"><title>Discussion</title><p id="Par27">The high efficacy and safety profiles of the latest generation pangenotypic DAAs, GLE/PIB and sofosbuvir/velpatasvir, have resulted in a high SVR12 rate for HCV patients of all genotypes and specific populations in the individual patient level [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. To unleash the true population-level effectiveness potential of these potent oral DAA regimens, multilevel barriers including complex pre-treatment assessments, patient compliance and high HCRU will need to be addressed to help achieve the World Health Organization&#8217;s goal of eliminating HCV as a major public health threat by 2030 [<xref ref-type="bibr" rid="CR8">8</xref>]. The universal short-duration of 8&#160;weeks for all treatment-na&#239;ve patients, regardless of the presence of cirrhosis or not, could help minimize the burden of pre-treatment assessments and improve the accessibility to DAA therapies [<xref ref-type="bibr" rid="CR18">18</xref>]. This benefit is of especial relevance as the epidemiology studies indicated that HCV infection has been shifting towards a predominantly treatment-na&#239;ve population [<xref ref-type="bibr" rid="CR28">28</xref>]. The present study provided complementary results to the EXPEDITION-8 trial that 8-week GLE/PIB regimen was as effective and safe in routine clinical practice as in the registered trial for treatment-na&#239;ve HCV patients with compensated cirrhosis.</p><p id="Par28">Another benefit of short treatment duration is regarding reduced HCRU. Analyzing the cost-effectiveness of healthcare costs with various treatment durations is beyond the scope of our present study. However, simplified clinic visit monitoring can enhance the capacity to scale-up DAA therapy and the COVID-19 pandemic has further highlighted the need for fewer clinic visits that minimize&#160;face-to-face contact. The mean number (mean&#8201;&#177;&#8201;SD) of clinic visits during the GLE/PIB treatment (from GLE/PIB initiation to SVR12 survey visit) was 5.3&#8201;&#177;&#8201;1.3 in the present study (Supplementary Table 5). This result is consistent with our previous TACR study that demonstrated the need of 5.94&#8201;&#177;&#8201;0.88 visits for patients receiving 8-week regimen, 6.90&#8201;&#177;&#8201;1.16 visits for patients receiving 12-week regimen, and 6.77&#8201;&#177;&#8201;1.07 visits for patients receiving 16-week regimen in a cohort of 3,144 patients receiving GLE/PIB (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001 for 8-week regimen vs. 12-week regimen) [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par29">The other potential benefit of short treatment duration is regarding the concern that treatment adherence can decline with longer treatment regimens [<xref ref-type="bibr" rid="CR29">29</xref>]. In the present real-world study, drug adherence for all the 301 patients were 80&#8211;100% in 285 (94.7%) patients, 60&#8211;80% in 4 (1.3%) patients, 40&#8211;60% in 6 (2.0%) patients, 20&#8211;40% in 3 (1.0%), and &lt; 20% in 3 (1%) patients. By mITT analysis, the treatment failure rates for the&#8201;&#8805;&#8201;80% and&#8201;&lt;&#8201;80% adherence groups were 1.5% (4/272) and 33.3% (1/3), respectively with an adjusted OR of 42.66 (95% CI 1.54&#8211;1185.30) for treatment failure for the&#8201;&lt;&#8201;80% adherence group (<italic toggle="yes">p</italic>&#8201;=&#8201;0.03). Shortening treatment duration without compromising SVR12 rates remains an important issue in HCV therapy, especially for the special populations [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par30">In addition to drug adherence, another factor associated with a higher risk of treatment failure in the present study is HCV RNA level&#8201;&#8805;&#8201;6,000,000&#160;IU/ml with an adjusted OR of 20.58 (95% CI 1.98&#8211;214.10, <italic toggle="yes">p</italic>&#8201;=&#8201;0.01) compared to HCV RNA level&#8201;&lt;&#8201;6,000,000&#160;IU/ml. Our result is in concordance with another real-world study which demonstrated that high viral load (&#8805;&#8201;10<sup>7</sup>&#160;IU/ml) was a significant predictor associated with virologic failure in non-cirrhotic genotype 2 patients receiving 8-week GLE/PIB therapy [<xref ref-type="bibr" rid="CR30">30</xref>]. These results suggest that more caution is needed with a short-course GLE/PIB regimen when treating HCV patients with a high viral load. In a meta-analysis of real-world data, the mITT SVR12 rate in treatment-na&#239;ve patients with compensated cirrhosis who received GLE/PIB treatment for 12&#160;weeks (n&#8201;=&#8201;362; 7 cohorts) was 99.0% [<xref ref-type="bibr" rid="CR31">31</xref>]. As a result, in order to ensure that a maximal percentage of patients can attain SVR12, a 12-week GLE/PIB regimen may be considered for this subgroup of patients with a high viral load of&#8201;&gt;&#8201;6,000,000&#160;IU/ml. Alternatively, as the virologic failure rate is low, those who failed the 8-week GLE/PIB can be treated with the 2<sup>nd</sup> line DAA. Since reports from the West did not identify high HCV viral load as a factor of GLE/PIB treatment failure for treatment-na&#239;ve patients with compensated cirrhosis, further research is needed to prove whether this is a phenomenon unique to Asian populations as well as the cost-effectiveness of management for this subgroup of patients.</p><p id="Par31">Our study evaluated the changes in common laboratory parameters during and after GLE/PIB therapy. The ALT and AST rapidly declined after therapy initiation (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). The albumin (<italic toggle="yes">p</italic>&#8201;=&#8201;0.03) and international ratio (INR) of prothrombin time (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01) improved less rapidly at the end of treatment. The total bilirubin level slightly increased during treatment (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01) and declined to below the baseline level after achieving SVR12 (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.01). All these changes in liver-related laboratory parameters were sustained after cessation of GLE/PIB treatment. This might indicate resolution of liver inflammation and improvement of liver function in accordance with the achievement of SVR12. Intriguingly, there was no significant change of creatinine levels throughout the course of GLE/PIB treatment as both GLE and PIB metabolism and clearance occur primarily in the biliary system and that renal excretion of each of the two medications is negligible.</p><p id="Par32">Our study revealed a high overall SVR12 rate of 98.2% (270/275) in the mITT population. For selected special patient groups including patients with HCV genotype 3, platelet count&#8201;&lt;&#8201;150,000 /&#181;l, FibroScan&#8201;&gt;&#8201;20&#160;kPa, or both platelet counts&#8201;&lt;&#8201;150,000/&#181;l and FibroScan&#8201;&gt;&#8201;20&#160;kPa, the SVR12 rates were 100% (6/6), 98.0% (144/147), 100.0% (12/12) and 100.0% (7/7), respectively (Table <xref rid="Tab3" ref-type="table">3</xref>). Among the five patients with virologic failure, one was the relapser, four were the non-responders and none had a breakthrough. Most non-virologic failure resulted from lost to follow-up or liver-unrelated mortalities (Table <xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par33">In line with other real-world studies, our large-scale real-world data demonstrated that 8-week GLE/PIB was well tolerated by HCV patients with cirrhosis [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR21">21</xref>&#8211;<xref ref-type="bibr" rid="CR26">26</xref>]. Although AEs were reported in as high as 24.9% (75/301) of the patients in the ITT population, almost all AEs were mild and had no clinical impacts. The most frequent AEs included fatigue (9.0%), pruritus (7.0%), insomnia (1.7%), skin rash (1.3%) and headache (1.0%) (Table <xref rid="Tab5" ref-type="table">5</xref>). Seven patients (2.3%) experienced serious AEs, including five liver-unrelated deaths, one pancreatitis and one hospitalization for unknown reasons. Two patients (0.7%) permanently discontinued GLE/PIB due to either poor drug compliance or hyperbilirubinemia. None of them were considered as GLE/PIB related.</p><p id="Par34">As a real-world observational study, there existed some inherent limitations for this study. First, because of the low prevalence rate of genotype 3&#8211;6 infection in Taiwan, the majority of the patient subgroups were genotypes 1 and 2. Second, because of inconsistent evaluations and incomplete assessments in real-world clinical practice, the information on AEs was subject to reporting biases, and the causal relationships between the AEs and the treatment could not be well-defined. Finally, as clinical diagnosis of liver cirrhosis is challenging, many different tools were employed in this study for diagnosis of cirrhosis.</p></sec><sec id="Sec15"><title>Conclusion</title><p id="Par35">This large-scale real-world Taiwanese cohort study demonstrated that 8-week GLE/PIB therapy was effective and well tolerated for treatment-na&#239;ve HCV patients with compensated cirrhosis. SVR12 rates were similarly high as in the clinical trials, including those with characteristics of advanced liver disease.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec16"><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12072_2023_10506_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file1 (DOCX 32 kb)</p></caption></media></supplementary-material></p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AE</term><def><p id="Par5">Adverse event</p></def></def-item><def-item><term>DAA</term><def><p id="Par6">Direct-acting antiviral</p></def></def-item><def-item><term>GLE</term><def><p id="Par7">Glecaprevir</p></def></def-item><def-item><term>HCC</term><def><p id="Par8">Hepatocellular carcinoma</p></def></def-item><def-item><term>HCRU</term><def><p id="Par9">Healthcare resource utilization</p></def></def-item><def-item><term>HCV</term><def><p id="Par10">Hepatitis C virus</p></def></def-item><def-item><term>PIB</term><def><p id="Par11">Pibrentasvir</p></def></def-item><def-item><term>SVR</term><def><p id="Par12">Sustained virologic response</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to thank the Taiwan Association for the Study of the Liver (TASL), the TASL Foundation and Taiwan Liver Research Foundation for grant support and the TACR study group for data collection. We also thank the Center for Medical informatics and Statistics of Kaohsiung Medical University for providing administrative and funding support.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors contributed to the study conception and design, material preparation, and data collection. The first draft of the manuscript was written by Te-Sheng Chang. Ming-Lung Yu and Chao-Hung Hung critically reviewed and commented on previous versions of the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The study was supported by grants from Kaohsiung Medical University (100CM-KMU-09, KMU-<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="KI110002">KI110002</ext-link>, MOST 108&#8211;2314-B-037 -066 -MY3, KMU-TC109B05 [Center for Liquid Biopsy and Cohort Research], KMU-TC109A04 [Center for Cancer Research]) and Kaohsiung Medical University Hospital (KMUH109-9R06, KMUH-DK(C)110011, KMUH-DK(C)110004, KMUH109-9R05).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data are available upon reasonable request to the corresponding authors.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par36">Ming-Lung Yu: Research support from Abbvie, Abbott, BMS, Gilead, Merck and Roche. Consultant for Abbvie, Abbott, Ascletis, BMS, Gilead, J&amp;J, Merck, Novartis, Pharmaessential and Roche. Speaker for Abbvie, Abbott, Ascletis, BMS, Gilead, Merck, Pharmaessential and Roche. Sheng-Shun Yang: Speaker for AbbVie, Bristol-Myers, Squibb, Gilead Sciences, Ipsen, and Merck Sharp &amp; Dohme. Advisory board member for AbbVie, Gilead Sciences, Hoffmann-LaRoche, and Ipsen.&#160;Te-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, Ching-Chu Lo, Chien-Wei Huang, Lee-Won Chong, Pin-Nan Cheng, Ming-Lun Yeh, Cheng-Yuan Peng, Chien-Yu Cheng, Jee-Fu Huang, Ming-Jong Bair, Chih-Lang Lin, Chi-Chieh Yang, Szu-Jen Wang, Tsai-Yuan Hsieh, Tzong-Hsi Lee, Pei-Lun Lee, Wen-Chih Wu, Chih-Lin Lin, Wei-Wen Su, Chia-Chi Wang, Jui-Ting Hu, Lein-Ray Mo, Chun-Ting Chen, Yi-Hsiang Huang, Chun-Chao Chang, Chia-Sheng Huang, Guei-Ying Chen, Chien-Neng Kao, Chi-Ming Tai, Chun-Jen Liu, Mei-Hsuan Lee, Pei-Chien Tsai, Chia-Yen Dai, Jia-Horng Kao, Han-Chieh Lin, Wang-Long Chuang, Chi-Yi Chen, Kuo-Chih Tseng, and&#160;Chao-Hung Hung&#160;declare no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World Health Organization. Hepatitis C. Geneva, Switzerland: WHO. 2022 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/hepatitis-c">https://www.who.int/news-room/fact-sheets/detail/hepatitis-c</ext-link>. Accessed Sep 2022</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chien</surname><given-names>RN</given-names></name><name name-style="western"><surname>Lu</surname><given-names>SN</given-names></name><name name-style="western"><surname>Pwu</surname><given-names>RF</given-names></name><name name-style="western"><surname>Wu</surname><given-names>GH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>WW</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CL</given-names></name></person-group><article-title>Taiwan accelerates its efforts to eliminate hepatitis C</article-title><source>Glob Health Med</source><year>2021</year><volume>3</volume><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.35772/ghm.2021.01064</pub-id><pub-id pub-id-type="pmid">34782872</pub-id><pub-id pub-id-type="pmcid">PMC8562095</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thrift</surname><given-names>AP</given-names></name><name name-style="western"><surname>El-Serg</surname><given-names>HB</given-names></name><name name-style="western"><surname>Kanwal</surname><given-names>F</given-names></name></person-group><article-title>Global epidemiology and burden of HCV infection and HCV-related disease</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2017</year><volume>14</volume><fpage>122</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2016.176</pub-id><pub-id pub-id-type="pmid">27924080</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>MH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>HI</given-names></name><name name-style="western"><surname>Lu</surname><given-names>SN</given-names></name><name name-style="western"><surname>Jen</surname><given-names>CL</given-names></name><name name-style="western"><surname>You</surname><given-names>SL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LY</given-names></name><etal/></person-group><article-title>Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study</article-title><source>J Inf Dis</source><year>2012</year><volume>206</volume><fpage>469</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis385</pub-id><pub-id pub-id-type="pmid">22811301</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cacoub</surname><given-names>P</given-names></name><name name-style="western"><surname>Desbois</surname><given-names>AC</given-names></name><name name-style="western"><surname>Comarmond</surname><given-names>C</given-names></name><name name-style="western"><surname>Saadoun</surname><given-names>D</given-names></name></person-group><article-title>Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis</article-title><source>Gut</source><year>2018</year><volume>67</volume><fpage>2025</fpage><lpage>2034</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2018-316234</pub-id><pub-id pub-id-type="pmid">29703790</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadler</surname><given-names>MD</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SS</given-names></name></person-group><article-title>Revolution in hepatitis C antiviral therapy</article-title><source>Br Med Bull</source><year>2015</year><volume>113</volume><fpage>31</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1093/bmb/ldv004</pub-id><pub-id pub-id-type="pmid">25680808</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falade-Nwulia</surname><given-names>O</given-names></name><name name-style="western"><surname>Suarez-Cuervo</surname><given-names>C</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>DR</given-names></name><name name-style="western"><surname>Fried</surname><given-names>MW</given-names></name><name name-style="western"><surname>Segal</surname><given-names>JB</given-names></name><name name-style="western"><surname>Sulkowski</surname><given-names>MS</given-names></name></person-group><article-title>Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review</article-title><source>Ann Intern Med</source><year>2017</year><volume>166</volume><fpage>637</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.7326/M16-2575</pub-id><pub-id pub-id-type="pmid">28319996</pub-id><pub-id pub-id-type="pmcid">PMC5486987</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">World Health Organization. Global hepatitis report. Geneva, Switzerland: WHO. 2017. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://apps.who.int/iris/bitstream/handle/10665/255016/9789?sequence=1">https://apps.who.int/iris/bitstream/handle/10665/255016/9789?sequence=1</ext-link>. Accessed in Sep 2022</mixed-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zoratti</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Siddiqua</surname><given-names>A</given-names></name><name name-style="western"><surname>Morassut</surname><given-names>RE</given-names></name><name name-style="western"><surname>Zeraatkar</surname><given-names>D</given-names></name><name name-style="western"><surname>Chou</surname><given-names>R</given-names></name><name name-style="western"><surname>van Holton</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: a systematic literature review and meta-analysis</article-title><source>EClinicalMedicine</source><year>2020</year><volume>18</volume><fpage>100237</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2019.12.007</pub-id><pub-id pub-id-type="pmid">31922124</pub-id><pub-id pub-id-type="pmcid">PMC6948236</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>KC</given-names></name><name name-style="western"><surname>Tung</surname><given-names>SY</given-names></name><name name-style="western"><surname>Wei</surname><given-names>KL</given-names></name><name name-style="western"><surname>Shen</surname><given-names>CH</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>YY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><fpage>13543</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-93095-x</pub-id><pub-id pub-id-type="pmid">34188161</pub-id><pub-id pub-id-type="pmcid">PMC8241842</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>AASLD-IDSA HCV Guidance Panel</collab></person-group><article-title>Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection</article-title><source>Clin Infect Dis</source><year>2018</year><volume>67</volume><fpage>1477</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy585</pub-id><pub-id pub-id-type="pmid">30215672</pub-id><pub-id pub-id-type="pmcid">PMC7190892</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>ML</given-names></name><name name-style="western"><surname>Chen</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Dai</surname><given-names>CY</given-names></name><name name-style="western"><surname>Hu</surname><given-names>TH</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CF</given-names></name><name name-style="western"><surname>Huang</surname><given-names>YS</given-names></name><etal/></person-group><article-title>2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population</article-title><source>J Formos Med Assoc</source><year>2020</year><volume>119</volume><fpage>1019</fpage><lpage>1040</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2020.04.003</pub-id><pub-id pub-id-type="pmid">32359879</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>European Association for the Study of the Liver</collab></person-group><article-title>EASL recommendations on treatment of hepatitis C: final update of the series</article-title><source>J Hepatol</source><year>2020</year><volume>73</volume><fpage>1170</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.08.018</pub-id><pub-id pub-id-type="pmid">36464532</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emmanuel</surname><given-names>B</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>EM</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>TR</given-names></name><name name-style="western"><surname>Kottilil</surname><given-names>S</given-names></name><name name-style="western"><surname>Lau</surname><given-names>G</given-names></name></person-group><article-title>Shortening the duration of therapy for chronic hepatitis C infection</article-title><source>Lancet Gastroenterol Hepatol</source><year>2017</year><volume>2</volume><fpage>832</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(17)30053-5</pub-id><pub-id pub-id-type="pmid">28802815</pub-id><pub-id pub-id-type="pmcid">PMC5737004</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andreoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Perri</surname><given-names>GD</given-names></name><name name-style="western"><surname>Persico</surname><given-names>M</given-names></name><name name-style="western"><surname>Marcellusi</surname><given-names>A</given-names></name><name name-style="western"><surname>Ethgen</surname><given-names>O</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Addressing HCV elimination barriers in Italy: healthcare resource utilization and cost impact using 8 weeks&#8217; glecaprevir/pibrentasvir therapy</article-title><source>Infect Dis Ther</source><year>2021</year><volume>10</volume><fpage>763</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1007/s40121-021-00410-0</pub-id><pub-id pub-id-type="pmid">33655410</pub-id><pub-id pub-id-type="pmcid">PMC7925258</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>CF</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>HT</given-names></name><name name-style="western"><surname>Chang</surname><given-names>TS</given-names></name><name name-style="western"><surname>Lo</surname><given-names>CC</given-names></name><name name-style="western"><surname>Hung</surname><given-names>CH</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><fpage>23473</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-03006-3</pub-id><pub-id pub-id-type="pmid">34873250</pub-id><pub-id pub-id-type="pmcid">PMC8648748</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">AbbVie. Mavyret (glecaprevir/pibrentasvir) US prescribing information. 2019. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209394s008lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209394s008lbl.pdf</ext-link><underline>.</underline> Accessed Sep 2022</mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>RS</given-names></name><name name-style="western"><surname>Buti</surname><given-names>M</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>L</given-names></name><name name-style="western"><surname>Chulanov</surname><given-names>V</given-names></name><name name-style="western"><surname>Chung</surname><given-names>WL</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>H</given-names></name><etal/></person-group><article-title>Glecaprevir/pibrentasvir for 8 weeks in treatment-na&#239;ve patients with chronic HCV genotypes 1&#8211;6 and compensated cirrhosis: the EXPEDITION-8 trial</article-title><source>J Hepatol</source><year>2020</year><volume>72</volume><fpage>441</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.10.020</pub-id><pub-id pub-id-type="pmid">31682879</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lampertico</surname><given-names>P</given-names></name><name name-style="western"><surname>Mauss</surname><given-names>S</given-names></name><name name-style="western"><surname>Persico</surname><given-names>M</given-names></name><name name-style="western"><surname>Barclay</surname><given-names>ST</given-names></name><name name-style="western"><surname>Marx</surname><given-names>S</given-names></name><name name-style="western"><surname>Lohmann</surname><given-names>K</given-names></name><etal/></person-group><article-title>Real-world clinical practice use of 8-week glecaprevir/pibrentasvir in treatment-na&#239;ve patients with compensated cirrhosis</article-title><source>Adv Ther</source><year>2020</year><volume>37</volume><fpage>4033</fpage><lpage>4042</lpage><pub-id pub-id-type="doi">10.1007/s12325-020-01449-0</pub-id><pub-id pub-id-type="pmid">32754824</pub-id><pub-id pub-id-type="pmcid">PMC7444399</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flamm</surname><given-names>SL</given-names></name><name name-style="western"><surname>Kort</surname><given-names>J</given-names></name><name name-style="western"><surname>Marx</surname><given-names>SE</given-names></name><name name-style="western"><surname>Strezewski</surname><given-names>J</given-names></name><name name-style="western"><surname>Dylla</surname><given-names>DE</given-names></name><name name-style="western"><surname>Bacon</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effectiveness of 8-week Glecaprevir/Pibrentasvir for treatment-na&#239;ve, compensated cirrhotic patients with chronic hepatitis C infection</article-title><source>Adv Ther</source><year>2020</year><volume>37</volume><fpage>2267</fpage><lpage>2274</lpage><pub-id pub-id-type="doi">10.1007/s12325-020-01301-5</pub-id><pub-id pub-id-type="pmid">32279176</pub-id><pub-id pub-id-type="pmcid">PMC7467488</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>PY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YY</given-names></name><name name-style="western"><surname>Lai</surname><given-names>JH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>HM</given-names></name><name name-style="western"><surname>Yao</surname><given-names>CT</given-names></name><name name-style="western"><surname>Liu</surname><given-names>IL</given-names></name><etal/></person-group><article-title>Real-world experience of chronic hepatitis c-related compensated liver cirrhosis treated with glecaprevir/pibrentasvir: a multicenter retrospective study</article-title><source>J Clin Med</source><year>2021</year><volume>10</volume><fpage>5236</fpage><pub-id pub-id-type="doi">10.3390/jcm10225236</pub-id><pub-id pub-id-type="pmid">34830518</pub-id><pub-id pub-id-type="pmcid">PMC8619604</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wedemeyer</surname><given-names>H</given-names></name><name name-style="western"><surname>Erren</surname><given-names>P</given-names></name><name name-style="western"><surname>Naumann</surname><given-names>U</given-names></name><name name-style="western"><surname>Rieke</surname><given-names>A</given-names></name><name name-style="western"><surname>Stoehr</surname><given-names>A</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>T</given-names></name><etal/></person-group><article-title>Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: real-world data from the German Hepatitis C-Registry</article-title><source>Liver Int</source><year>2021</year><volume>41</volume><fpage>949</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1111/liv.14829</pub-id><pub-id pub-id-type="pmid">33592123</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klinker</surname><given-names>H</given-names></name><name name-style="western"><surname>Naumann</surname><given-names>U</given-names></name><name name-style="western"><surname>R&#246;ssle</surname><given-names>M</given-names></name><name name-style="western"><surname>Berg</surname><given-names>T</given-names></name><name name-style="western"><surname>Bondin</surname><given-names>M</given-names></name><name name-style="western"><surname>Lohmann</surname><given-names>K</given-names></name><etal/></person-group><article-title>Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: safety and effectiveness data from the German Hepatitis C-Registry</article-title><source>Liver Int</source><year>2021</year><volume>41</volume><fpage>1518</fpage><lpage>1522</lpage><pub-id pub-id-type="doi">10.1111/liv.14937</pub-id><pub-id pub-id-type="pmid">33966349</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>YH</given-names></name><name name-style="western"><surname>Lu</surname><given-names>CK</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CH</given-names></name><name name-style="western"><surname>Tung</surname><given-names>SY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YH</given-names></name><name name-style="western"><surname>Yen</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><issue>8</issue><fpage>e0272567</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0272567</pub-id><pub-id pub-id-type="pmid">35980912</pub-id><pub-id pub-id-type="pmcid">PMC9387785</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cornberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Ahumada</surname><given-names>A</given-names></name><name name-style="western"><surname>Aghemo</surname><given-names>A</given-names></name><name name-style="western"><surname>Andreoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Bhagat</surname><given-names>A</given-names></name><name name-style="western"><surname>Butrymowicz</surname><given-names>I</given-names></name><etal/></person-group><article-title>Safety and effectiveness using 8 weeks of glecaprevir/pibrentasvir in HCV-infected treatment-na&#239;ve patients with compensated cirrhosis: the CREST study</article-title><source>Adv Ther</source><year>2022</year><volume>39</volume><fpage>3146</fpage><lpage>3158</lpage><pub-id pub-id-type="doi">10.1007/s12325-022-02158-6</pub-id><pub-id pub-id-type="pmid">35543964</pub-id><pub-id pub-id-type="pmcid">PMC9239949</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CF</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>PN</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>KC</given-names></name><name name-style="western"><surname>Lo</surname><given-names>CC</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>HT</given-names></name><etal/></person-group><article-title>Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: a real-world nationwide hepatitis C virus registry programme in Taiwan</article-title><source>Liver Int</source><year>2021</year><volume>41</volume><fpage>1265</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.1111/liv.14849</pub-id><pub-id pub-id-type="pmid">33655714</pub-id><pub-id pub-id-type="pmcid">PMC8252422</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>PN</given-names></name><name name-style="western"><surname>Mo</surname><given-names>LR</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CF</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>HT</given-names></name><etal/></person-group><article-title>Sofosbuvir/velpatasvir for hepatitis C virus infection: real-world effectiveness and safety from a nationwide registry in Taiwan</article-title><source>Infect Dis Ther</source><year>2022</year><volume>11</volume><fpage>485</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1007/s40121-021-00576-7</pub-id><pub-id pub-id-type="pmid">34967920</pub-id><pub-id pub-id-type="pmcid">PMC8847492</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#252;ppe</surname><given-names>D</given-names></name><name name-style="western"><surname>Stoehr</surname><given-names>A</given-names></name><name name-style="western"><surname>Stoehr</surname><given-names>P</given-names></name><name name-style="western"><surname>Stoehr</surname><given-names>S</given-names></name><name name-style="western"><surname>Klinker</surname><given-names>H</given-names></name><name name-style="western"><surname>Klinker</surname><given-names>G</given-names></name><etal/></person-group><article-title>The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: real-world data from the German Hepatitis C Registry (DHC-R)</article-title><source>J Viral Hepat</source><year>2021</year><volume>28</volume><fpage>1474</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1111/jvh.13586</pub-id><pub-id pub-id-type="pmid">34339561</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>T</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>K</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>LA</given-names></name><name name-style="western"><surname>Sidharthan</surname><given-names>S</given-names></name><name name-style="western"><surname>Silk</surname><given-names>R</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>A</given-names></name><etal/></person-group><article-title>High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study</article-title><source>Hepatol Int</source><year>2016</year><volume>10</volume><fpage>310</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1007/s12072-015-9680-7</pub-id><pub-id pub-id-type="pmid">26612014</pub-id><pub-id pub-id-type="pmcid">PMC4778154</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>WM</given-names></name><name name-style="western"><surname>Wei</surname><given-names>KL</given-names></name><name name-style="western"><surname>Tung</surname><given-names>SY</given-names></name><name name-style="western"><surname>Shen</surname><given-names>CH</given-names></name><name name-style="western"><surname>Chang</surname><given-names>TS</given-names></name><name name-style="western"><surname>Yen</surname><given-names>CW</given-names></name><etal/></person-group><article-title>High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy</article-title><source>J Formos Med Assoc</source><year>2020</year><volume>11</volume><fpage>1593</fpage><lpage>1600</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2020.08.010</pub-id><pub-id pub-id-type="pmid">32839045</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lampertico</surname><given-names>P</given-names></name><name name-style="western"><surname>Crrion</surname><given-names>JA</given-names></name><name name-style="western"><surname>Curry</surname><given-names>M</given-names></name><name name-style="western"><surname>Turnes</surname><given-names>J</given-names></name><name name-style="western"><surname>Cornberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Negro</surname><given-names>F</given-names></name><etal/></person-group><article-title>Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis C infection: a meta-analysis</article-title><source>J Hepatol</source><year>2020</year><volume>72</volume><fpage>1112</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.01.025</pub-id><pub-id pub-id-type="pmid">32061651</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>